Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| Diagnostics | 39.4 | 39.2 | 42.4 | 41.1 | 33.2 | 34.3 | 31.2 | 31.9 |
| Life Science | 17.5 | 26.5 | 25.4 | 70.1 | 55.1 | 41.9 | 32.3 | 53.3 |
| Total revenues | 56.9 | 65.7 | 67.8 | 111.2 | 88.3 | 76.2 | 63.5 | 85.3 |
| Revenue growth [+] | -35.6% | -13.8% | 6.7% | 30.5% | -4.9% | 18.8% | -25.1% | 48.8% |
| Diagnostics | 18.6% | 14.2% | 36.0% | 28.7% | 9.5% | 15.1% | 44.4% | -8.6% |
| Life Science | -68.2% | -36.8% | -21.5% | 31.5% | -11.9% | 22.0% | -48.9% | 138.5% |
| Cost of goods sold | 25.4 | 31.7 | 31.0 | 42.8 | 39.2 | 31.5 | 26.4 | 27.5 |
| Gross profit | 31.5 | 34.0 | 36.7 | 68.5 | 49.2 | 44.7 | 37.1 | 57.8 |
| Gross margin | 55.4% | 51.8% | 54.2% | 61.6% | 55.6% | 58.7% | 58.4% | 67.8% |
| Selling, general and administrative [+] | 19.4 | 18.6 | 21.3 | 26.1 | 22.4 | 19.7 | 18.2 | 19.5 |
| Sales and marketing | 8.3 | 7.8 | 8.2 | 7.5 | 7.7 | 7.0 | 6.2 | 6.5 |
| General and administrative | 11.1 | 10.8 | 13.1 | 18.6 | 14.7 | 12.7 | 12.0 | 12.9 |
| Research and development | 6.2 | 6.4 | 6.0 | 5.7 | 6.2 | 6.1 | 6.1 | 6.1 |
| Other operating expenses | 32.9 | 7.5 | 11.8 | | 0.3 | 6.1 | 0.4 | |
| EBITDA [+] | -22.7 | 5.5 | 1.7 | 40.9 | 24.5 | 16.9 | 16.2 | 35.9 |
| EBITDA growth | -193.0% | -67.3% | -89.8% | 13.7% | -39.8% | 64.6% | -52.3% | 139.3% |
| EBITDA margin | -40.0% | 8.4% | 2.4% | 36.7% | 27.7% | 22.2% | 25.5% | 42.2% |
| Depreciation | 1.6 | 1.6 | 1.6 | 1.7 | 1.7 | 1.8 | 1.7 | 1.6 |
| EBITA | -24.4 | 3.9 | 0.0 | 39.2 | 22.8 | 15.1 | 14.5 | 34.4 |
| EBITA margin | -42.9% | 6.0% | 0.0% | 35.2% | 25.8% | 19.8% | 22.8% | 40.3% |
| Amortization of intangibles | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.3 | 2.1 | 2.1 |
| EBIT [+] | -26.9 | 1.5 | -2.5 | 36.7 | 20.3 | 12.8 | 12.4 | 32.2 |
| EBIT growth | -232.8% | -88.6% | -119.8% | 13.9% | -45.1% | 111.0% | -59.2% | 167.0% |
| EBIT margin | -47.3% | 2.2% | -3.6% | 33.0% | 23.0% | 16.8% | 19.6% | 37.8% |
| Non-recurring items [+] | 1.2 | -3.2 | 4.2 | 0.6 | | 4.3 | -3.3 | -2.0 |
| Restructuring charges | 1.2 | -3.2 | 4.2 | 0.1 | | | 0.3 | |
| Legal settlement | | | | 0.5 | | | | 1.0 |
| Loss on contingent liability | | | | | | 4.6 | -3.6 | -3.0 |
| Interest expense, net [+] | 0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 |
| Interest expense | 0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 |
| Other income (expense), net [+] | -0.8 | 0.2 | 0.3 | 0.7 | -0.2 | -0.2 | 0.1 | -0.7 |
| Other | 0.8 | 1.3 | 2.4 | 3.3 | 0.9 | 1.1 | 1.4 | 2.0 |
| Pre-tax income | -29.1 | 4.6 | -6.6 | 36.5 | 19.8 | 7.9 | 15.3 | 33.1 |
| Income taxes | 0.7 | -1.1 | 0.7 | 7.8 | 4.4 | 1.2 | 3.6 | 6.8 |
| Tax rate | | | | 21.3% | 22.3% | 15.3% | 23.7% | 20.4% |
| Net income | -29.8 | 5.7 | -7.3 | 28.8 | 15.3 | 6.7 | 11.7 | 26.3 |
| Net margin | -52.4% | 8.7% | -10.8% | 25.8% | 17.4% | 8.7% | 18.4% | 30.8% |
| |
| Basic EPS [+] | ($0.68) | $0.13 | ($0.17) | $0.66 | $0.35 | $0.15 | $0.27 | $0.61 |
| Growth | -292.4% | -14.9% | -162.5% | 8.5% | -43.2% | 1.6% | -58.1% | 178.3% |
| Diluted EPS [+] | ($0.68) | $0.13 | ($0.16) | $0.65 | $0.35 | $0.15 | $0.26 | $0.60 |
| Growth | -295.0% | -15.0% | -162.4% | 9.0% | -43.0% | 0.6% | -58.4% | 173.7% |
| |
| |
| Shares outstanding (basic) [+] | 43.9 | 43.6 | 43.6 | 43.5 | 43.4 | 43.3 | 43.3 | 43.2 |
| Growth | 1.1% | 0.7% | 0.6% | 0.7% | 0.8% | 0.9% | 1.2% | 1.0% |
| Shares outstanding (diluted) [+] | 43.9 | 44.4 | 44.5 | 44.3 | 44.0 | 44.0 | 44.1 | 44.1 |
| Growth | -0.3% | 0.8% | 0.9% | 0.3% | 0.6% | 1.9% | 1.9% | 2.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|